STAT+: Pharmalittle: We’re reading about Medicare price negotiations, slowing layoffs, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Category: pharmalittle
STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Pharmalittle: We’re reading about a Vertex pain pill, an abortion pill hearing, and more
Top of the morning to you. And a fine one it is. Despite gray skies,…
.jpg)
STAT+: Pharmalittle: We’re reading about Medicaid and sickle cell, pharma CEOs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Sanders jabbing Merck’s CEO, fixing drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: We’re reading about Lilly’s gene therapy for hearing, Shkreli’s life-long ban, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: We’re reading about FDA warnings on CAR-T drugs, a Sanofi deal, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: We’re reading about Lilly plant problems, FDA reorganization plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Sanders targeting pharma CEOs, insider trading, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: We’re reading about a CRISPR approval, selling meds directly to patients, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
.jpg)
STAT+: Pharmalittle: We’re reading about Wegovy shipments, the NIH director’s plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more
And so, another working week will soon come to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: We’re reading about Sanofi’s Olympics bet, Singulair problems, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharmalittle: We’re reading about LillyDirect, India’s drug standards, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news
And so, another working week will soon come to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news
Hello, everyone, and how are you today? We are doing fine, thank you, especially given…
STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles
Good morning, everyone, and welcome to another working week, and a new year, as well….
STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud
And so, another working week will soon come to a close. Not a moment too…
STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily…
STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernathy to step down as Verily CMO
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market
Good morning, everyone, and nice to see you again after an extended break on this…
Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in…
STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup
Hello, everyone. Damian Garde here, filling in for Ed Silverman on what is an abbreviated…
STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs
Good morning and welcome to Thanksgiving week! STAT reporter Andrew Joseph here filling in for…
STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs
And so, another working week will soon draw to a close Not a moment too…
STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…